Steven Siegel, MD, PhD

Franz Alexander Endowed Chair in Psychiatry

Chair and Professor, Department of Psychiatry and the Behavioral Sciences

Professor of Neurological Surgery, and Population and Public Health Sciences, Keck School of Medicine

Professor of Biomedical Engineering, Viterbi School of Engineering

Chief Mental Health and Wellness Officer, Keck Medicine of USC

Vice President for Behavioral Health, Office of the SVP for Health Affairs

Image of Steven Siegel, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Steven Siegel was appointed Professor and Chair of the Department of Psychiatry and the Behavioral Sciences at the Keck School of Medicine of USC in July 2016. He is a physician-scientist specializing in the treatment of psychosis. Dr. Siegel came to USC after 20 years at the University of Pennsylvania, where he had roles in research, teaching and clinical care. He received his B.A. in Neuroscience at Colgate University in 1986, and his M.D. and Ph.D. in Neurobiology at the Mount Sinai School of Medicine in 1996. He later completed a MacArthur Foundation Training Fellowship before completing his residency in Psychiatry and a Fellowship in Neuropsychiatry at the University of Pennsylvania. Prior to joining USC, Dr. Siegel was involved in, medical, undergraduate and graduate education. He was Associate Director of Masters in Translational Research for 6 years at the University of Pennsylvania. He directed a course on Therapeutics and Commercialization at Penn, based on his experience with technology transfer. Other major educational roles at Penn included Director of the Clinical Training Program that spanned 6 clinical specialties. He was named one of the nation’s outstanding clinicians by the National Association for Mental Illness. Dr. Siegel has made contributions to understanding the neurobiology of schizophrenia, autism, and drug dependence. His laboratory uses animal models to evaluate EEG, combined with behavioral and molecular studies. Additionally, he invented, patented, and licensed a new method of treatment for schizophrenia using biodegradable implants, which successfully completed a pivotal Phase 3 clinical trial and has been submitted as an NDA to the FDA for consideration. In his current role as Chair of the Department of Psychiatry and the Behavioral Sciences, Dr. Siegel oversees operations for a department comprised of 200 faculty members, 50 staff members and 100 residents, fellows, and trainees; more than tripling the size of the department in 5 years since he arrived. His department provides a broad range of mental health services to children and adults at LAC+USC Medical Center including Emergency, Inpatient, and Outpatient Services. Additionally, he has expanded and improved the quality of mental health services at Keck Medicine and USC Care, with an emphasis on consultation liaison and specialty services. During his first year at USC he designed and oversaw the incorporation of student mental health services into Keck Medicine of USC. He continues to lead and guide the evolution of student mental health services at USC, both within Student Health, and in the new Keck Medicine student outpatient practice that launched in late 2019. He was named the inaugural Chief Mental Health and Wellness Officer for Keck Medicine of USC in 2021, with responsibility and oversight of mental health services across the Keck enterprise as well as leadership of wellness program as part of Keck Medicine’s nationally acclaimed Care for the Caregiver program. Over his career at Penn and USC, Dr. Siegel has mentored more than 150 graduate and undergraduate trainees in neuroscience and bioengineering. His research has been supported by federal, state, foundation, and industry sources for more than 25 years. He has published approximately 150 manuscripts as well as multiple book chapters, and one book spanning topics related to drug abuse, basic research in schizophrenia and autism, as well as clinical aspects of schizophrenia.

Publications

  • Multiomic Immune Profiling of Pediatric Transplant Recipients Identifies Cell States Associated with Vaccine Response. Clin J Am Soc Nephrol. 2026 Apr 01; 21(4):650-663.. View in PubMed
  • Protein-protein interaction-interfering peptide rescues dysregulated NMDA receptor signaling. JCI Insight. 2026 Jan 23; 11(2).. View in PubMed
  • Comparing Computerized Adaptive Testing-Mental Health (CAT-MH) and Behavioral Health Measure-20 (BHM-20) screening measures in college mental health. J Am Coll Health. 2026 Jan 12; 1-7.. View in PubMed
  • Retraction Note: mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia. Mol Psychiatry. 2025 Jul; 30(7):3358.. View in PubMed
  • Editorial Expression of Concern: Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia. Mol Psychiatry. 2025 Jul; 30(7):3359.. View in PubMed
  • Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant. medRxiv. 2025 Feb 26.. View in PubMed
  • Protocol of randomized-controlled trial to examine the effectiveness of three different interventions to reduce healthcare provider burnout. BMC Health Serv Res. 2024 Dec 23; 24(1):1643.. View in PubMed
  • LiFT (a Lithium Fiber-Based Test): An At-Home Companion Diagnostics for a Safer Lithium Therapy in Bipolar Disorder. Adv Healthc Mater. 2024 07; 13(18):e2304122.. View in PubMed
  • Editorial Expression of Concern: Altered neuregulin 1-erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia. Nat Med. 2024 Mar; 30(3):911.. View in PubMed
  • Theta-frequency medial septal nucleus deep brain stimulation increases neurovascular activity in MK-801-treated mice. Front Neurosci. 2024; 18:1372315.. View in PubMed